8-K current report · filed Nov 2, 2026

Clorox (CLX) 8-K Current Report: November 2, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2CLX overview

Short answer

Clorox (CLX) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Fiscal Q1 2026 results for quarter ended September 30, 2026.

Clorox 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal Q1 2026 results for quarter ended September 30, 2026
  • Full financial results and management commentary in Exhibit 99.1
  • Investor focus: quarterly performance, outlook and impacts from Clorox’s ongoing recovery efforts

Item 7.01 · Regulation FD Disclosure

  • Supplemental financial information for fiscal year 2026, provided in Exhibit 99.2
  • Exhibit may contain additional operating or financial metrics relevant to investor analysis

Item EX-99.1 · Exhibit EX-99.1

  • Q1 FY2027 net sales rose 33% to $1.91B, with GOJO contributing 15 points and ERP-transition comparisons contributing materially to organic growth
  • Adjusted EPS increased 82% to $1.55, while gross margin fell 130 basis points to 40.4% from higher commodity and logistics costs
  • GOJO integration scaling through Clorox Purell ProCare, with Health and Wellness sales up 62% and segment adjusted EBIT up 69%
  • FY2027 sales outlook maintained at 13%-14% growth, but gross margin reduced to about 41.5% and adjusted EPS expected near the $5.70-$6.00 range low end
  • Inflationary pressure is the key risk, with higher costs and negative mix offsetting savings, pricing actions and acquisition synergies

Item EX-99.2 · Exhibit EX-99.2

  • Q1 FY2027 net sales $1.905B, up 33%, with 15% from GOJO acquisition and 18% organic growth
  • Health and Wellness led growth at 62%, including 39% acquisition impact and 23% organic growth
  • Gross margin 40.4%, down 130 basis points, pressured by commodities and manufacturing/logistics costs
  • Adjusted EPS $1.55, up 82%, versus GAAP EPS $1.39, up 114%, despite $26M GOJO costs
  • FY2027 adjusted EPS outlook $5.70 to $6.00, including expected $46M GOJO acquisition and integration costs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Clorox 8-K filings

Get the next CLX 8-K as it lands

Follow CLX for push alerts, or ask the research agent what this filing means.